BioSpace News Archive

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS-CoV-2 Antigen Test to the U.S. Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 antigens in people with active infections in 15 minutes.

OncoSec Medical Incorporated, a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

DIABETESpredict®, a first of its kind predictive genetic test for type 2 diabetes, is now being administered to help improve patient outcomes during the COVID-19 pandemic.

Two Markham, Ontario based natural health companies announced a strategic partnership to expand the availability of ANOSMIC® COVID-19 Smell Tester in the Canadian market.

Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize the SARS-CoV-2 U.K. strain, also known as B.1.1.7 lineage or VOC 202012/01.